Alector Announces Pricing of Underwritten Offering

Impact · against what's priced in

Alector is raising $75 million through a significant share issuance, which extends its cash runway into late 2027 but creates immediate dilution for shareholders. While the offering is priced at a slight premium, the scale of the issuance outweighs the modest price uplift.

ALEC−0.10

No priced-in read yet

In context

The issuance of 36.6 million shares at $2.05 provides critical funding to sustain operations into late 2027, but the resulting dilution offsets the benefit of the 7.3% pricing premium.

Read from the article alone

• biotech
• ALEC
• capital raise
• equity financing
• neurodegeneration
• stock offering

Search tags